These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Poor outcomes in methamphetamine-associated cardiomyopathy-a growing health issue in New Zealand. Wang TKM; Kueh SA; Sutton T; Gabriel R; Lund M; Looi JL N Z Med J; 2019 Sep; 132(1502):55-66. PubMed ID: 31563927 [TBL] [Abstract][Full Text] [Related]
24. Clinical Course of Methamphetamine-Induced Psychotic Disorder in a 3-Month Follow-Up. Javadian S; Shabani A; Shariat SV Prim Care Companion CNS Disord; 2016 Nov; 18(6):. PubMed ID: 27907276 [TBL] [Abstract][Full Text] [Related]
25. Caring for Hospitalized Adults with Methamphetamine Use Disorder: A Proposed Clinical Roadmap. Priest KC; Balasanova AA; Levander XA; Chan B; Blazes CK; Mahan J; Brown J; Mahoney S; Peng L; Mahoney S; Lundy T; Englander H Am J Med; 2023 Jun; 136(6):507-509. PubMed ID: 36739062 [No Abstract] [Full Text] [Related]
26. Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. Todd G; Burns L; Pearson-Dennett V; Esterman A; Faulkner PL; Wilcox RA; Thewlis D; Vogel AP; White JM Drug Alcohol Depend; 2019 Dec; 205():107595. PubMed ID: 31600615 [TBL] [Abstract][Full Text] [Related]
27. DARK Classics in Chemical Neuroscience: Methamphetamine. Abbruscato TJ; Trippier PC ACS Chem Neurosci; 2018 Oct; 9(10):2373-2378. PubMed ID: 29602278 [TBL] [Abstract][Full Text] [Related]
31. Characteristics of Methamphetamine-associated Cardiomyopathy and the Impact of Methamphetamine Use on Cardiac Dysfunction. Reddy PK; Chau E; Patel SV; Yang K; Ng TM; Elkayam U Am J Cardiol; 2021 Sep; 154():86-91. PubMed ID: 34233837 [TBL] [Abstract][Full Text] [Related]
32. Methamphetamine: geographic areas and populations at risk, and emerging evidence for effective interventions. Degenhardt L; Baker A; Maher L Drug Alcohol Rev; 2008 May; 27(3):217-9. PubMed ID: 18368601 [No Abstract] [Full Text] [Related]
34. Pulmonary arterial hypertension seen in methamphetamine abusers. Thompson CA Am J Health Syst Pharm; 2008 Jun; 65(12):1109-10. PubMed ID: 18541676 [No Abstract] [Full Text] [Related]
35. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley. Gibson DR; Leamon MH; Flynn N J Psychoactive Drugs; 2002; 34(3):313-9. PubMed ID: 12422943 [TBL] [Abstract][Full Text] [Related]
36. First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine. McKetin R; Hides L; Kavanagh DJ; Saunders JB; Dawe S Schizophr Res; 2018 Sep; 199():456-457. PubMed ID: 29680188 [No Abstract] [Full Text] [Related]
37. Stroke and methamphetamine use in young adults: a review. Lappin JM; Darke S; Farrell M J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1079-1091. PubMed ID: 28835475 [TBL] [Abstract][Full Text] [Related]
38. Epidemiology of methamphetamine abuse in Missouri. Topolski JM Mo Med; 2007; 104(1):82-8. PubMed ID: 17410832 [TBL] [Abstract][Full Text] [Related]
39. Comparison of crystalline methamphetamine ("ice") users and other patients with toxicology-related problems presenting to a hospital emergency department. Dargan PI; Wood DM Med J Aust; 2008 Aug; 189(4):234. PubMed ID: 18707575 [No Abstract] [Full Text] [Related]